other material
confidence high
sentiment positive
materiality 0.80
Cogent announces positive initial Phase 2 APEX data for bezuclastinib in advanced systemic mastocytosis
Cogent Biosciences, Inc.
- All 11 patients achieved ≥50% serum tryptase reduction; median reduction 89%.
- All 8 evaluable patients had ≥50% bone marrow mast cell reduction; six cleared aggregates.
- No periorbital/peripheral edema, cognitive effects, or intracranial bleeding reported.
- Two prior avapritinib patients showed similar benefit; all remained on study at cutoff.
- Company to accelerate timelines; next APEX update by end of 2022; SUMMIT data in H1 2023.